DCLK1 is most frequently mutated in stomach adenocarcinomas (STAD, 10.6%), uterine corpus endometrial carcinoma (UCEC, 9.2%) and colon adenocarcinomas (COAD, 8.7%), while copy number variation gains are most frequently observed in rectal adenocarcinomas (READ, 69.5%), COAD (56.3%), and STAD (37%) (Figure S2A). Here, DCLK1 is linked to colon adenocarcinoma.